ERCC1 Antibody (8F1)

ERCC1 Monoclonal Antibody for Western blot, IHC (P), FACS, IP

>> See 6 other antibodies for ERCC1 (DNA excision repair protein ERCC-1)
Synonyms:
DNA excision repair protein ERCC-1
Entrez Gene ID:
UniProt ID:
Details
Host / Isotype: Mouse / IgG2b
Class: Monoclonal
Type: Antibody
Clone: 8F1
Tested Species Reactivity: Human (Hu), Mouse (Ms), Rat (Rt)
Published Species Reactivity: Hamster (Hm), Human (Hu)
Immunogen: Recombinant full length human ERCC1 protein
Ordering Information
Pierce ERCC1 Antibody (8F1)
Product #
MA5-13912
Size
500 ul
Price
$320.00
Purchase
Add ERCC1 Antibody (8F1) to your cart.
Tested Applications Dilution *
Western Blot (WB) Assay Dependent
Immunohistochemistry (Paraffin) (IHC (P)) 1:100-1:500
Flow Cytometry (FACS) 0.5-1ug/test
Immunoprecipitation (IP) Assay Dependent
Published Applications Dilution
Western Blot (WB) See publications below
Immunohistochemistry (IHC) See publications below
* Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
Form Information
Form: Liquid
Concentration: 0.2mg/ml
Purification: Protein A
Storage Buffer: PBS, pH 7.4, with 0.2% BSA
Preservative: 0.09% sodium azide
Storage Conditions: 4° C
Product Specific Information
MA5-13912 targets ERCC1 in IP, IHC (P), FACS and WB applications and shows reactivity with human, mouse and rat samples.

The MA5-13912 immunogen is recombinant full length human ERCC1 protein.
General Information
The mammalian ERCC1 (Excision Repair Cross Complementing) polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination. NER mechanism involves dual incisions on both sides of the damage catalyzed by two nucleases. In mammalian cells XPG cleaves 3' of the DNA lesion while the ERCC1-XPF complex makes the 5' incision. Elevated levels of ERCC1 have also been reported in Cisplatin-resistant cells.
Product Images
  • ERCC1 Antibody (MA5-13912) in WB
    MA5-13912_WB.jpg

    Western Blot with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_WB.jpg)

    Western Blot with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Western blot analysis of ERCC1 was performed by loading 25 ug of Hela cell lysates onto an SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked at 4ºC overnight. The membrane was probed with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1:200 overnight at 4°C, washed in TBST, and probed with an HRP-conjugated secondary antibody for 1 hr at room temperature in the dark. Chemiluminescent detection was performed using Pierce ECL Plus Western Blotting Substrate (Product # 32132). Results show a band at ~39 kDa.
  • ERCC1 Antibody (MA5-13912) in IHC (P)
    MA5-13912_IHC_Human_lung_carcinoma_20130613152407.jpg

    Immunohistochemistry (Paraffin) with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_IHC_Human_lung_carcinoma_20130613152407.jpg)

    Immunohistochemistry (Paraffin) with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Human lung adenocarcinoma (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
  • ERCC1 Antibody (MA5-13912) in IHC (P)
    MA5-13912_IHC_Human_tonsil_tissue_20130613152432.jpg

    Immunohistochemistry (Paraffin) with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_IHC_Human_tonsil_tissue_20130613152432.jpg)

    Immunohistochemistry (Paraffin) with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Human tonsil tissue (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
  • ERCC1 Antibody (MA5-13912) in IHC (P)
    MA5-13912_IHC_Rat_lymph_node_tissue_20130613152457.jpg

    Immunohistochemistry (Paraffin) with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_IHC_Rat_lymph_node_tissue_20130613152457.jpg)

    Immunohistochemistry (Paraffin) with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Rat lymph node (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
  • ERCC1 Antibody (MA5-13912) in FACS
    MA5-13912_FACS_Hela.jpg

    Flow Cytometry with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_FACS_Hela.jpg)

    Flow Cytometry with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Flow cytometry analysis of ERCC1 in Hela cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/ml, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1ug/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
  • ERCC1 Antibody (MA5-13912) in FACS
    MA5-13912_FACS_HepG2.jpg

    Flow Cytometry with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_FACS_HepG2.jpg)

    Flow Cytometry with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Flow cytometry analysis of ERCC1 in HepG2 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/ml, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1ug/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
  • ERCC1 Antibody (MA5-13912) in FACS
    MA5-13912_FACS_NIH-3T3.jpg

    Flow Cytometry with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912) (MA5-13912_FACS_NIH-3T3.jpg)

    Flow Cytometry with anti-ERCC1 Monoclonal Antibody [8F1] (MA5-13912)

    Flow cytometry analysis of ERCC1 in NIH-3T3 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/ml, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 0.5ug/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
Publications:
Western Blot
  Species / Dilution Summary
  Hm / 1:200
MA5-13912 was used in western blot to investigate the role of ERCC1/XPF endonuclease in DNA repair in Chinese hamster cell line UV4

Nucleic Acids Res. 2008 Jan;36(1):1-9.
"The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells."
Author(s): Al-Minawi AZ, Saleh-Gohari N, Helleday T
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13912 was used in western blot to investigate the molecular mechanisms of spontaneous mesenchymal stem cell transformation

PLoS One. 2008 Jan 2;3(1):e1398.
"Molecular characterization of spontaneous mesenchymal stem cell transformation."
Author(s): Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez-Fernandez LA, Lloyd AC, Garcia-Castro J, Bernad A
Number of Citations: 14
(See PubMed article )
Immunohistochemistry
  Species / Dilution Summary
  Hu / 1:200
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1, hRad51, and BRCA1 protein expression in patients with stage III/IV non-small cell lung cancer

Lung Cancer. 2005 Nov;50(2):211-9.
"ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy."
Author(s): Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ
Number of Citations: 8
(See PubMed article )
  Hu / 1:300
MA5-13912 was used in immunohistochemistry to study the role of ERCC1 in repairing DNA in non-small-cell lung cancer treated with cisplatin

N Engl J Med. 2006 Sep 7;355(10):983-91.
"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy."
Author(s): Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators
Number of Citations: 124
(See PubMed article )
  Hu / 1:300
MA5-13912 was used in immunohistochemistry to compare the expression of diagnostic biomarkers in bronchial biopsies and surgical specimens of non-small-cell lung cancer

Ann Oncol. 2007 Jun;18(6):1043-50.
"Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer."
Author(s): Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria JC
Number of Citations: 5
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to investigate the clinical significance of breast cancer resistance protein in small-cell lung cancer

Lung Cancer. 2009 Jul;65(1):105-11.
"Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer."
Author(s): Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai A
Number of Citations: 1
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to study the efficacy of combined cetuximab and modified FOLFOX6 treatment in a phase II gastric cancer trial

Br J Cancer. 2009 Jan 27;100(2):298-304.
"Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer."
Author(s): Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY
Number of Citations: 15
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to investigate the prognostic significance of excision repair cross complementing group 1 in adrenocortical carcinoma patients

Endocr Relat Cancer. 2009 Sep;16(3):907-18.
"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy."
Author(s): Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M
Number of Citations: 1
(See PubMed article )
  Hu / 1:400
MA5-13912 was used in immunohistochemistry to investigate ERCC1, RPA and XPF expression in different types of smokers with lung adenocarcinoma

Ann Oncol. 2009 Jul;20(7):1257-63.
"The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma."
Author(s): Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC, Fouret P
Number of Citations: 1
(See PubMed article )
  Hu / 1:50
MA5-13912 was used in immunohistochemistry to study the predictive and prognostic value of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin

Jpn J Clin Oncol. 2010 Apr;40(4):286-93.
"Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin."
Author(s): Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL
Number of Citations: 2
(See PubMed article )
  Hu / 1:300
MA5-13912 was used in immunohistochemistry to study the roles of ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung

J Thorac Oncol. 2010 Apr;5(4):453-9.
"ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival."
Author(s): Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A
Number of Citations: 0
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to investigate the prognostic effectiveness of thymidylate synthase in the chemotherapy of malignant pleural mesothelioma

J Clin Oncol. 2010 Mar 20;28(9):1534-9.
"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy."
Author(s): Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13912 was used in immunohistochemistry to evaluate excision repair cross-complementation group 1 ERCC1 as a biomarker for treatment of advanced non-small-cell lung cancer

Ann Oncol. 2010 Sep;21(9):1817-24.
"ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial."
Author(s): Vilmar AC, Santoni-Rugiu E, Sørensen JB
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13912 was used in immunohistochemistry to detect advanced lung cancer using the ERCC1 biomarker

Eur J Cancer. 2010 Jun;46(9):1554-62.
"ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial."
Author(s): Vilmar A, Santoni-Rugiu E, Sørensen JB
Number of Citations: 3
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to investigate the effect of specific markers for adrenocortical carcinoma prognosis after specific chemotherapy

Endocr Relat Cancer. 2010 Sep;17(3):797-807.
"Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma."
Author(s): Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13912 was used in immunohistochemistry to study biomarkers for predicting the response to capecitabine and cisplatin combination chemotherapy in metastatic oesophageal squamous cell cancer

Br J Cancer. 2010 Sep 7;103(6):845-51.
"Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma."
Author(s): Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH
Number of Citations: 2
(See PubMed article )
  Hu / 0
MA5-13912 was used in immunohistochemistry to investigate the relationship of ERCC1 expression with survival of ovarian cancer patients

Gynecol Oncol. 2010 Nov;119(2):325-31.
"Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma."
Author(s): Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A
Number of Citations: 1
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to study the association of low ERCC1 expression with poor survival in cervical cancer patients treated with radiation therapy

Radiother Oncol. 2010 Nov;97(2):352-9.
"Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone."
Author(s): Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM
Number of Citations: 3
(See PubMed article )
  Hu / 1:50
MA5-13912 was used in immunohistochemistry to study the molecular and clinical determinants of survival in pancreatic cancer patients treated with second-line chemotherapy

Anticancer Res. 2010 Oct;30(10):4289-95.
"Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey."
Author(s): Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN
Number of Citations: 1
(See PubMed article )
  Hu / 1:25
MA5-13912 was used in immunohistochemistry to investigate the prognostic significance of multiple genes for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy

Biomarkers. 2011 Feb;16(1):74-82.
"Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy."
Author(s): Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ
Number of Citations: 0
(See PubMed article )
  Hu / 1:100
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression levels in patients with uterine cervical adenocarcinoma

Int J Gynecol Cancer. 2011 Nov;21(8):1479-85.
"The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma."
Author(s): Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S, Udagawa Y
Number of Citations: 1
(See PubMed article )
  Hu / 0
MA5-13912 was used in immunohistochemistry to characterize ERCC1 protein in squamous cell carcinomas of the head and neck and the effects of treatment

Head Neck. 2012 Jun;34(6):785-91.
"Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status."
Author(s): Hao D, Lau HY, Eliasziw M, Box A, Diaz R, Klimowicz AC, Shin B, Lees-Miller SP, Magliocco AM
Number of Citations: 1
(See PubMed article )
  Hu / 2 ug/ml
MA5-13912 was used in immunohistochemistry to study the role of deficient expression of DNA repair enzymes in early progression to sporadic colon cancer

Genome Integr. 2012 Apr 11;3(1):3.
"Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer."
Author(s): Facista A, Nguyen H, Lewis C, Prasad AR, Ramsey L, Zaitlin B, Nfonsam V, Krouse RS, Bernstein H, Payne CM, Stern S, Oatman N, Banerjee B, Bernstein C
Number of Citations: 0
(See PubMed article )
  Hu / 1:50
MA5-13912 was used in immunohistochemistry to study the outcomes of gefitinib treatment in head and neck cancer patients

Clin Cancer Res. 2012 Sep 15;18(18):5123-33.
"Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02)."
Author(s): Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, Grall D, Penault-Llorca F, Dassonville O, Bertucci F, Cayre A, De Raucourt D, Geoffrois L, Finetti P, Giraud P, Racadot S, Morinière S, Sudaka A, Van Obberghen-Schilling E, Milano G
Number of Citations: 0
(See PubMed article )
(This product is for In Vitro experimental use only. Not for resale without express authorization.)
Part of Thermo Fisher Scientific